<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709512</url>
  </required_header>
  <id_info>
    <org_study_id>POLARIS2015-003</org_study_id>
    <nct_id>NCT02709512</nct_id>
  </id_info>
  <brief_title>Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin</brief_title>
  <acronym>ATOMIC</acronym>
  <official_title>Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polaris Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polaris Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme
      versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate
      synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine,
      an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the
      malignant pleural mesothelioma cells will starve and die.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>approximately 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>approximately 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Drug: ADI-PEG 20 plus Pem Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
In Combination With:
Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo plus Pem Cis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
In Combination With:
Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADI-PEG 20 plus Pem Cis</intervention_name>
    <description>Investigational Drug in combination approved standard of care treatment for this indication</description>
    <arm_group_label>Drug: ADI-PEG 20 plus Pem Cis</arm_group_label>
    <other_name>Pemetrexed</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo plus Pem Cis</intervention_name>
    <description>Placebo in combination approved standard of care treatment for this indication</description>
    <arm_group_label>Drug: Placebo plus Pem Cis</arm_group_label>
    <other_name>Pemetrexed</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven advanced MPM of biphasic or sarcomatoid histology. Biphasic MPM
             is defined using the World Health Organization's international histological
             classification of tumors as containing an epithelial and a sarcomatoid component with
             each component comprising at least 10% of the tumor

          2. Na√Øve to prior chemotherapy or immunotherapy (i.e., this is a first-line systemic
             therapy study).

          3. MPM tumor sample for determination of ASS1 status. ASS1-deficiency is not required for
             study entry at study start, but tumor sample for ASS1 status is required. This study
             will employ an adaptive biomarker-driven design with an interim analysis to be
             conducted at the end of the phase 2 portion. The interim analysis will evaluate the
             treatment effect of ADI PEG 20 in combination with pemetrexed and cisplatin on overall
             survival (OS) in the overall population (biphasic and sarcomatoid histology patients)
             and pre-defined subpopulation of biomarker-positive patients (ASS1-deficient
             subpopulation). Thus ASS1 deficiency may be required for the phase 3 portion of the
             study, pending the interim analysis. ASS1-deficiency, demonstrated on tissue specimen
             (cytospin samples are not acceptable), will be defined in the laboratory manual. If
             archived tissue is not sufficient or not available, then tissue must be obtained by
             biopsy.

          4. Measurable disease as assessed by modified RECIST for MPM for thoracic disease
             (Appendix A) and RECIST 1.1 for extra-thoracic disease (Appendix B).

          5. ECOG performance status of 0 - 1 (Appendix C).

          6. Predicted life expectancy of at least 12 weeks.

        Exclusion Criteria:

          1. Radiotherapy (except for palliative reasons) the previous two weeks before.

          2. Ongoing toxic manifestations of previous treatments.

          3. Symptomatic brain or spinal cord metastases (patients must be stable for &gt; 1 month
             post radiotherapy or surgery).

          4. Major thoracic or abdominal surgery from which the patient has not yet recovered.

          5. Serious infection requiring treatment with intravenous antibiotics at the time of
             study entrance, or an infection requiring intravenous therapy within 7 days prior.

          6. Known to be serologically positive for human immunodeficiency virus (HIV). Testing to
             determine possible infection status is not required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S Bomalaski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Polaris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phuong Lee</last_name>
    <phone>858-452-6688</phone>
    <phone_ext>188</phone_ext>
    <email>plee@polarispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Ross, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology - Santa Monica</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Olvesky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Helen Diller Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Jahan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Antonia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedy Kindler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Marlene &amp; Stewart Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Miller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Rybkin, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Mansfield, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne S Tsao, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tweed Hospital (NNSW LHD)</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2486</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehtesham Abdi, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandria Hospital and Health Services</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken O'Byrne, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Adelaide Local Health Network, Inc.</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Karapetis, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inn-Wen Chong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Experimental Cancer Medicine (CECM)</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Szlosarek, M.D. PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

